Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Gossamer Bio is downgraded due to the recent failure of their PROSERA trial, which fell short of expectations and has raised concerns about the company's ability to find a registrational path for their drug Seralutinib. The company's financials also suffer from high levels of convertible debt and the need for additional financings, which may hinder their progress in bringing their pipeline products to market. Despite the potential upside in addressing diseases such as PH-ILD, the overall execution and confidence in the company's management has been called into question.

Bears say

Gossamer Bio is facing multiple challenges, including underwhelming data and regulatory uncertainty for its lead product Seralutinib in the PAH market. The company's financials are also a cause for concern as they have a significant amount of debt and will likely need additional financing to reach commercialization. As a result, a downgrade to Neutral is justified due to these fundamental issues.

GOSS has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 8 analysts, GOSS has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.